Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone and Bevacizumab in Brain Metastases From Malignant Solid Tumors
NCT07449481Phase 2Withdrawn
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of utidelone in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start May 2026; status: withdrawn.
02
Drugs
utidelone
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07449481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449481.